 OncLive | Managing Dermatologic Toxicities Associated With Targeted Therapies OncLive mTOR inhibitors including temsirolimus (Torisel) and everolimus (Afinitor) are commonly associated with rash. Grade 4 rashes are not common, but if they do occur, treatment should be stopped immediately. Other common symptoms associated with mTOR ... |
